| Last month, we were pleased to share that the amyloid plaque targeted drug was being brought to a FDA advisory committee review. The drug was unfortunately not recommended for approval by this advisory committee. This decision comes with mixed feelings across the field. The Alzheimer’s Association plans to continue to advocate for approval. Please stay tuned for updates. |
